General Information of Drug (ID: DMRWDX5)

Drug Name
A-134974 Drug Info
Synonyms a-134974; GTPL5130; CHEMBL1591918; ZINC3827162; SMP2_000021; NCGC00186045-01; A134974; A 134974
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Terminated [1]
Cross-matching ID
PubChem CID
9885936
TTD Drug ID
DMRWDX5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Adenosine kinase (ADK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GP-3269 DM035LO Convulsion 8A68.Z Phase 1 [3]
ABT-702 DMYJMV9 Pain MG30-MG3Z Terminated [4]
GP-683 DMPODL9 Pain MG30-MG3Z Terminated [5]
GP515 DMRUIX3 Discovery agent N.A. Investigative [6]
5'-iodotubercidin DML5ZEJ Discovery agent N.A. Investigative [7]
MB-03966 DM9KLQC Epileptic seizures 8A61-8A6Z Investigative [8]
5-iodo,5'-deoxytubercidin DMVT2LW Discovery agent N.A. Investigative [9]
6-Benzylthioinosine DMNXGZP Discovery agent N.A. Investigative [10]
Iodotubercidin DMQMH6S Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine kinase (ADK) TTL732K ADK_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5130).
2 Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J Pharmacol Exp Ther. 2001Feb;296(2):501-9.
3 Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20.
4 ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93(2-3):78-88.
5 The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth Analg. 1997 Sep;85(3):675-80.
6 Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 2001 Jan;296(1):99-105.
7 Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage. 2005 Mar;13(3):250-7.
8 Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells. Neurotherapeutics. 2009 April; 6(2): 278-283.
9 Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes. J Med Chem. 2006 Nov 16;49(23):6726-31.
10 Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. Bioorg Med Chem. 2010 May 15;18(10):3403-12.
11 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.